Study of Gene Activity in Fat and Muscle in Diabetics and Healthy Controls
|ClinicalTrials.gov Identifier: NCT00412906|
Recruitment Status : Completed
First Posted : December 19, 2006
Last Update Posted : May 21, 2008
|Condition or disease||Intervention/treatment|
|Healthy Type 2 Diabetes Endotoxemia||Drug: Escherichia Coli Endotoxin|
Numerous studies have shown an association between low-grade inflammation and insulin-resistance in type 2 diabetics. It is also well-known that septic patients often develop insulin-resistance. The pathogenetic mechanisms behind the association between inflammation and insulin-resistance is not fully understood.
In this study we create an experimental inflammation by giving E. coli endotoxin 0,3 ng/kg iv to type 2 diabetics and healthy controls. Muscle biopsies are taken at 0, 2, 4 and 6 hours after injection, while fat biopsies are taken 0, 2, 4, 6 and 8 hours after endotoxin. mRNA for adiponectin, leptin, PPAR-gamma, PGC-1, PAI-1 and cytokines in tissue is later measured by RT-PCR.
Blood samples are drawn on an hourly basis until 8 hours after endotoxin injection for common biochemical analyses including white blood cell count. Plasma is spared and later analyzed for cytokines, PAI-1 and VCAM-1/ICAM-1.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||48 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Study of Gene Expression in Fat and Muscle Tissue in Type 2 Diabetics and Healthy Controls During Experimental Endotoxemia|
|Study Start Date :||November 2006|
|Primary Completion Date :||April 2008|
|Study Completion Date :||April 2008|
- Gene expression evaluated by measuring mRNA via RT-PCR. Plasma cytokine content, PLasma PAI-1 content, endotoxemia score
- Mean Arterial Pressure, heart rate, Temperature,
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00412906
|Centre of Inflammaiton and Metabolism, Rigshospitalet|
|Copenhagen, Denmark, 2100|
|Principal Investigator:||Anne Sofie Andreasen, MD||Rogshospitalet, Denmark|